表紙
市場調查報告書

載體篩選 (各產品·技術·各國資料·常染色體隱性疾病):全球市場分析·預測 (2019-2029年)

Global Carrier Screening Market: Focus on Product Type, Technology Type, 18 Countries Data, Disease Type, Industry Insights, and Competitive Landscape - Analysis and Forecast, 2019-2029

出版商 BIS Research Inc. 商品編碼 882259
出版日期 內容資訊 英文 201 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
載體篩選 (各產品·技術·各國資料·常染色體隱性疾病):全球市場分析·預測 (2019-2029年) Global Carrier Screening Market: Focus on Product Type, Technology Type, 18 Countries Data, Disease Type, Industry Insights, and Competitive Landscape - Analysis and Forecast, 2019-2029
出版日期: 2019年06月27日內容資訊: 英文 201 Pages
簡介

全球載體篩選市場到2029年前預計將達到29億3,000萬美元的規模。

本報告提供全球載體篩選市場調查,提供市場概要,市場成長的各種影響因素及市場機會分析,各市場區隔·各地區的趨勢與市場規模的變化與預測,競爭環境,主要企業的簡介等系統性資訊。

摘要整理

第1章 市場概要

第2章 市場動態

  • 影響分析
  • 市場成長的推動要素
  • 市場成長的阻礙因素
  • 市場機會

第3章 競爭情形

  • 主要策略·發展
  • 市場佔有率分析

第4章 產業分析

  • 恰當的使用標準
  • American College of Obstetricians and Gynecologists (ACOG)
  • American College of Medical Genetics and Genomics (ACMG)
  • U.S. Food and Drug Administration (FDA)

第5章 全球載體篩選市場:各產品類型

  • 實驗室開發試驗 (LDT)
  • 套件·化驗

第6章 全球載體篩選市場:各疾病

  • 唐氏症
  • 鐮狀細胞貧血症 (SCA)
  • 囊狀纖維化症 (CF)
  • 血友病
  • 脊髓性肌萎縮症 (SMA)
  • 脆弱性X症候群
  • 地中海型貧血
  • 其他常染色體性隱性遺傳病

第7章 全球載體篩選市場:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他

第8章 企業簡介

  • 概要
  • 23andMe, Inc.
  • BGI
  • CENTOGENE AG
  • Eurofins Scientific
  • Gene By Gene
  • GenMark Diagnostics, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Pathway Genomics Corporation
  • Quest Diagnostics Incorporated
  • Sema4
  • Thermo Fisher Scientific Inc.

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BH142A

Global Carrier Screening Market to Reach $2.93 Billion by 2029

Key Questions Answered in this Report:

  • How the carrier screening market is expected to have an impact on the healthcare industry?
  • What was the total revenue generated by the global carrier screening market for autonomous in 2018 and how is it expected to grow during 2019 - 2029?
  • How are the transformational trends and major driving forces in this technology are expected to yield new business opportunities?
  • Which sub-segment of the global carrier screening market by disease, such as down syndrome, sickle cell anemia, cystic fibrosis, hemophilia, spinal muscular atrophy, fragile x syndrome, thalassemia, other autosomal recessive genetic disorders, during the forecast period, 2019-2029?
  • Which region, such as North America, Europe, Asia-Pacific, Latin-America is expected to grow the fastest in the global carrier screening market?
  • What are the key developmental strategies which are being implemented by the key players to stand out in this market?

Global Carrier Screening Market Forecast, 2019-2029

The global carrier screening Industry Analysis by BIS Research projects the market to grow with a double-digit compound annual growth rate between the years 2019 and 2029. The global carrier screening market was valued at $846.9 million in 2018 and is estimated to grow over $2.93 billion by 2029.

With substantial increase in the demand for carrier screening test and diagnostics tests based on sequencing, the carrier screening market is expected to witness an impressive growth and promises to be a lucrative field for investment.

Expert Quote on Global Carrier Screening Market

"North America is the leading contributor to the global carrier screening market and is noticed to be contributing more than 51.82% of the global market values. However, Asia-Pacific is expected to grow at an impressive 15.97% CAGR in the forecast period from 2019 to 2029. Currently, the Asia-Pacific market is estimated to contribute approximately 15.11% of total global market value."

Scope of the Market Intelligent on the Global Carrier Screening Market

The purpose of this market analysis is to gain a holistic view of the carrier screening market in terms of various influencing factors, such as trends, technological advancements, and funding scenario in the market. The scope of this report constitutes of an in-depth study of the global carrier screening market, including a thorough analysis of the products across different regions.

Market Segmentation

The global carrier screening market is segmented on the basis of four sections, namely product, technology, disease type, and geography.

Under the global carrier screening market segmentation by product type, the laboratory developed tests sub-segment dominated the global carrier screening market in 2018. However, the NGS-based carrier screening test is expected to witness the highest CAGR in the forecast period from 2019 to 2029.

Under the global carrier screening market segmentation by disease type, down syndrome currently dominates the global carrier screening market. Cystic fibrosis disease type is estimated to witness the highest CAGR in the forecast period.

The global carrier screening market segmentation by region is segregated under five major regions, such as North America, Europe, APAC, Latin America, and Rest-of-the-World. North America was the leading contributor of the global carrier screening market in 2018.

Key Companies in the Carrier Screening Market

The key players which have significant contributions to the carrier screening market include Illumina, Inc., Myriad Genetics, Inc., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics, Natera, Inc., Invitae Corporation, Eurofins Scientific, GenMark Diagnostics, 23and Me, Inc., Sema4, BGI, Centogene AG, Pathway Genomics, and Gene By Gene.

Table of Contents

Executive Summary

1 Market Overview

2 Market Dynamics

  • 2.1 Impact Analysis
  • 2.2 Market Drivers
    • 2.2.1 Availability of Advanced Screening Technologies
    • 2.2.2 Shift of Reimbursement Policies Toward More Genetics Coverage
    • 2.2.3 Increasing Consumer Demand
  • 2.3 Market Restraints
    • 2.3.1 Limited Clinical Experience
    • 2.3.2 General Public May Lack Interest in Expanded Carrier Screening
    • 2.3.3 Technical Challenges of the Knowledge Base and Newer Sequencing Platforms
  • 2.4 Market Opportunities
    • 2.4.1 Enhancement and Adoption of Carrier Screening Products through Utilization of DTC
    • 2.4.2 Capitalizing on the Potential Presented by the Emerging Markets of Asia

3 Competitive Landscape

  • 3.1 Key Strategies and Developments
    • 3.1.1 Collaboration and Partnership
    • 3.1.2 Business Expansion
    • 3.1.3 Product Launch and Product Approval
    • 3.1.4 Acquisitions
  • 3.2 Market Share Analysis

4 Industry Insights

  • 4.1 Appropriate Use Criteria
    • 4.1.1 Carrier Screening for Familial Disease
      • 4.1.1.1 Fragile X
    • 4.1.2 Carrier Screening for Common and Ethnic Genetic Diseases
      • 4.1.2.1 Cystic Fibrosis
      • 4.1.2.2 Spinal Muscular Atrophy
      • 4.1.2.3 Hemoglobinopathies
      • 4.1.2.4 Ashkenazi Jewish Carrier Screening
    • 4.1.3 Other Ethnicities
  • 4.2 American College of Obstetricians and Gynecologists (ACOG)
  • 4.3 American College of Medical Genetics and Genomics (ACMG)
  • 4.4 U.S. Food and Drug Administration (FDA)

5 Global Carrier Screening Market (by Product Type)

  • 5.1 Laboratory Developed Tests (LDT)
  • 5.2 Kits and Assays

6 Global Carrier Screening Market (by Disease)

  • 6.1 Thalassemia
  • 6.2 Fragile X Syndrome
  • 6.3 Sickle Cell Anemia
  • 6.4 Spinal Muscular Atrophy
  • 6.5 Hemophilia
  • 6.6 Cystic Fibrosis
  • 6.7 Other Autosomal Recessive Genetic Disorders

7 Global Carrier Screening Market (by Region)

  • 7.1 North America
    • 7.1.1 North America: Market Dynamics
    • 7.1.2 North America Carrier Screening Market (by Country)
      • 7.1.2.1 U.S.
      • 7.1.2.2 Canada
  • 7.2 Europe
    • 7.2.1 Europe: Market Dynamics
    • 7.2.2 Europe Carrier Screening Market (by Country)
      • 7.2.2.1 Germany
      • 7.2.2.2 U.K.
      • 7.2.2.3 France
      • 7.2.2.4 Italy
      • 7.2.2.5 Spain
      • 7.2.2.6 The Netherlands
      • 7.2.2.7 Belgium
      • 7.2.2.8 Switzerland
      • 7.2.2.9 Denmark
      • 7.2.2.10 Rest-of-Europe
  • 7.3 Asia-Pacific
    • 7.3.1 Asia-Pacific: Market Dynamics
    • 7.3.2 Asia-Pacific, by Country
      • 7.3.2.1 China
      • 7.3.2.2 Japan
      • 7.3.2.3 Australia
      • 7.3.2.4 India
      • 7.3.2.5 South Korea
      • 7.3.2.6 Singapore
      • 7.3.2.7 Rest-of-the-Asia-Pacific
  • 7.4 Latin America
    • 7.4.1 Latin America: Market Dynamics
    • 7.4.2 Latin America, by Country
      • 7.4.2.1 Brazil
      • 7.4.2.2 Mexico
      • 7.4.2.3 Rest-of-Latin America
  • 7.5 Rest-of-the-World

8 Company Profiles

  • 8.1 Overview
  • 8.2 23andMe, Inc.
    • 8.2.1 Company Overview
    • 8.2.2 Role of 23andMe, Inc. in the Global Carrier Screening Market
    • 8.2.3 SWOT Analysis
  • 8.3 BGI
    • 8.3.1 Company Overview
    • 8.3.2 Role of BGI in the Global Carrier Screening Market
    • 8.3.3 SWOT Analysis
  • 8.4 CENTOGENE AG
    • 8.4.1 Company Overview
    • 8.4.2 Role of CENTOGENE AG in the Global Carrier Screening Market
    • 8.4.3 SWOT Analysis
  • 8.5 Eurofins Scientific
    • 8.5.1 Company Overview
    • 8.5.2 Role of Eurofins Scientific in the Global Carrier Screening Market
    • 8.5.3 Financials
    • 8.5.4 SWOT Analysis
  • 8.6 Gene By Gene
    • 8.6.1 Company Overview
    • 8.6.2 Role of Gene by Gene in the Global Carrier Screening Market
    • 8.6.3 SWOT Analysis
  • 8.7 GenMark Diagnostics, Inc.
    • 8.7.1 Company Overview
    • 8.7.2 Role of GenMark Diagnostics, Inc. in the Global Carrier Screening Market
    • 8.7.3 Financials
    • 8.7.4 Key Insights about Financial Health of the Company
    • 8.7.5 SWOT Analysis
  • 8.8 Illumina, Inc.
    • 8.8.1 Company Overview
    • 8.8.2 Role of Illumina, Inc. in the Global Carrier Screening Market
    • 8.8.3 Financials
    • 8.8.4 Key Insights about Financial Health of the Company
    • 8.8.5 SWOT Analysis
  • 8.9 Invitae Corporation
    • 8.9.1 Company Overview
    • 8.9.2 Role of Invitae Corporation in the Global Carrier Screening Market
    • 8.9.3 Financials
    • 8.9.4 Key Insights about Financial Health of the Company
    • 8.9.5 SWOT Analysis
  • 8.10 Laboratory Corporation of America Holdings
    • 8.10.1 Company Overview
    • 8.10.2 Role of Laboratory Corporation of America Holdings in the Global Carrier Screening Market
    • 8.10.3 Financials
    • 8.10.4 SWOT Analysis
  • 8.11 Myriad Genetics, Inc.
    • 8.11.1 Company Overview
    • 8.11.2 Role of Myriad Genetics, Inc. in the Global Carrier Screening Market
    • 8.11.3 Financials
    • 8.11.4 SWOT Analysis
  • 8.12 Natera, Inc.
    • 8.12.1 Company Overview
    • 8.12.2 Role of Natera, Inc. in the Global Carrier Screening Market
    • 8.12.3 Financials
      • 8.12.3.1 Key Insights of the Financial Health about the Company
    • 8.12.4 SWOT Analysis
  • 8.13 Pathway Genomics Corporation
    • 8.13.1 Company Overview
    • 8.13.2 Role of Pathway Genomics Corporation in the Global Carrier Screening Market
    • 8.13.3 SWOT Analysis
  • 8.14 Quest Diagnostics Incorporated
    • 8.14.1 Company Overview
    • 8.14.2 Role of Quest Diagnostics Incorporated in the Global Carrier Screening Market
    • 8.14.3 Financials
    • 8.14.4 SWOT Analysis
  • 8.15 Sema4
    • 8.15.1 Company Overview
    • 8.15.2 Role of Sema4 in the Global Carrier Screening Market
    • 8.15.3 SWOT Analysis
  • 8.16 Thermo Fisher Scientific Inc.
    • 8.16.1 Company Overview
    • 8.16.2 Role of Thermo Fisher Scientific Inc. in the Global Carrier Screening Market
    • 8.16.3 Financials
    • 8.16.4 Key Insights about Financial Health of the Company
    • 8.16.5 SWOT Analysis

List of Tables

  • Table 2.1: Impact Analysis
  • Table 4.1: ACMG: American College of Medical Genetics and Genomics; ACOG: American College of Obstetricians and Gynecologists: Recommendations for Risk-Based Screening
  • Table 4.2: List of Regulatory Authorities involved in CLIA Program
  • Table 4.3: Regulatory Bodies
  • Table 6.1: Commercially Available Thalassemia Carrier Screening Tests
  • Table 6.2: Thalassemia Carrier Screening Market Adoption and Market Growth, 2018
  • Table 6.3: Commercially Available Fragile X Syndrome Carrier Screening Tests
  • Table 6.4: Fragile X Syndrome Carrier Screening Market Adoption and Market Growth, 2018
  • Table 6.5: Commercially Available Sickle Cell Anaemia Carrier Screening Tests
  • Table 6.6: Sickle Cell Anaemia Carrier Screening Market Adoption and Market Growth, 2018
  • Table 6.7: Commercially Available SMA Carrier Screening Tests
  • Table 6.8: SMA Carrier Screening Market Adoption and Market Growth, 2018
  • Table 6.9: Commercially Available Hemophilia Carrier Screening Tests
  • Table 6.10: Hemophilia Carrier Screening Market Adoption and Market Growth, 2018
  • Table 6.11: Commercially Available CF Carrier Screening Tests
  • Table 6.12: CF Carrier Screening Market Adoption and Market Growth, 2018

List of Figures

  • Figure 1: Drivers and Restraints of Carrier Screening Market
  • Figure 2: Key Strategies Incorporated by Stakeholders of Carrier Screening Market, to Sustain the Competition (from January 2015 to May 2019)
  • Figure 3: Global Carrier Screening Market, 2018-2029
  • Figure 4: Global Carrier Screening Market Share (by Product), 2018 and 2029
  • Figure 5: Global Carrier Screening LDT Market Share (by Technology), 2018 and 2029
  • Figure 6: Global Carrier Screening Market Share (by Disease Type), 2018 and 2029
  • Figure 7: Global Carrier Screening Market Share (by Region), 2018 and 2029
  • Figure 1.1: End-to-End Practice Workflow Support for Genetic Screening
  • Figure 1.2: Autosomal Recessive Inheritance of Harmful Mutations
  • Figure 1.3: The Journey to Expanded Carrier Screening
  • Figure 2.1: Market Dynamics of Global Carrier Screening Market
  • Figure 3.1: Competitive Landscape, January 2015-May 2019
  • Figure 3.2: Share of Key Developments and Strategies, January 2015-May 2019
  • Figure 3.3: Collaborations and Partnership Share (by Company), January 2015-May 2019
  • Figure 3.4: Business Expansion Share (by Company), January 2015-May 2019
  • Figure 3.5: Product Launch Share (by Company), January 2015-May 2019
  • Figure 3.6: Acquisitions Share (by Company), January 2015-May 2019
  • Figure 3.7: Market Share Analysis (by Company) for the Global Carrier Screening Market, 2018
  • Figure 4.1: Classification of Tests in CLIA Program
  • Figure 5.1: Global carrier screening Market (by Product Type)
  • Figure 5.2: Global Carrier Screening Market (by Product Type), 2018 and 2029
  • Figure 5.3: Key players of Carrier Screening Test Market
  • Figure 5.4: Global Carrier Screening Test Market, 2018-2029
  • Figure 5.5: Global Carrier Screening Test Market (by Technology), 2018 and 2029, $Million
  • Figure 5.6: Global Carrier Screening Laboratory Developed Test Market (NGS Technology), 2018-2029, $Million
  • Figure 5.7: Global Carrier Screening Laboratory Developed Test Market (PCR Technology), 2018-2029, $Million
  • Figure 5.8: Global Carrier Screening Laboratory Developed Test Market (Other Technology), 2018-2029, $Million
  • Figure 5.9: Key Players of the Kits and Assays Associated with Carrier Screening Market
  • Figure 5.10: Global Carrier Screening Kits and Assays Market, 2018-2029
  • Figure 6.1: Different Types of Autosomal Recessive Genetic Diseases
  • Figure 6.2: Global Carrier Screening Market (by Disease), 2018 and 2029
  • Figure 6.3: Global Carrier Screening Market (Thalassemia), 2018-2029
  • Figure 6.4: Thalassemia Carrier Screening Market Regional Penetration, 2018, 2023 and 2029
  • Figure 6.5: Thalassemia Carrier Screening Market Regional Penetration by Country, 2018 and 2029
  • Figure 6.6: Global Carrier Screening Market (Fragile X Syndrome), 2018-2029
  • Figure 6.7: Fragile X Syndrome Carrier Screening Market Regional Penetration, 2018, 2023 and 2029
  • Figure 6.8: Fragile X Syndrome Carrier Screening Market Regional Penetration by Country, 2018 and 2029
  • Figure 6.9: Global Carrier Screening Market (Sickle Cell Anaemia), 2018-2029
  • Figure 6.10: Sickle Cell Anaemia Carrier Screening Market Regional Penetration, 2018, 2023 and 2029
  • Figure 6.11: Sickle Cell Anaemia Carrier Screening Market Regional Penetration by Country, 2018 and 2029
  • Figure 6.12: Global Carrier Screening Market (Spinal Muscular Atrophy), 2018-2029
  • Figure 6.13: SMA Carrier Screening Market Regional Penetration, 2018, 2023 and 2029
  • Figure 6.14: SMA Carrier Screening Market Regional Penetration by Country, 2018 and 2029
  • Figure 6.15: Global Carrier Screening Market (Hemophilia), 2018-2029
  • Figure 6.16: Hemophilia Carrier Screening Market Regional Penetration, 2018, 2023 and 2029
  • Figure 6.17: Hemophilia Carrier Screening Market Regional Penetration by Country, 2018 and 2029
  • Figure 6.18: Global Carrier Screening Market (Cystic Fibrosis), 2018-2029
  • Figure 6.19: CF Carrier Screening Market Regional Penetration, 2018, 2023 and 2029
  • Figure 6.20: CF Carrier Screening Market Regional Penetration by Country, 2018, 2023 and 2029
  • Figure 6.21: Global Carrier Screening Market (Other Autosomal Recessive Genetic disorders), 2018-2029
  • Figure 7.1: Global Carrier Screening Market (by Region), 2019 and 2029
  • Figure 7.2: North America: Carrier Screening Market, (2018-2029)
  • Figure 7.3: North America: Market Dynamics
  • Figure 7.4: North America: Carrier Screening Market (by Country), 2018 and 2029
  • Figure 7.5: The U.S.: Carrier Screening Market, 2018-2029
  • Figure 7.6: Canada: Carrier Screening Market, 2018-2029
  • Figure 7.7: Europe: Carrier Screening Market (2018-2029)
  • Figure 7.8: Europe: Market Dynamics
  • Figure 7.9: Europe: Carrier Screening Market (by Country), 2018 and 2029
  • Figure 7.10: Germany: Carrier Screening Market (2018-2029)
  • Figure 7.11: U.K.: Carrier Screening Market, 2018-2029
  • Figure 7.12: France: Carrier Screening Market, 2018-2029
  • Figure 7.13: Italy: Carrier Screening Market, 2018-2029
  • Figure 7.14: Spain: Carrier Screening Market, 2018-2029
  • Figure 7.15: The Netherlands: Carrier Screening Market, 2018-2029
  • Figure 7.16: Belgium: Carrier Screening Market, 2018-2029
  • Figure 7.17: Switzerland: Carrier Screening Market, 2018-2029
  • Figure 7.18: Denmark: Carrier Screening Market, 2018-2029
  • Figure 7.19: Rest-of-Europe: Carrier Screening Market, 2018-2029
  • Figure 7.20: Asia-Pacific: Carrier Screening Market, (2018-2029)
  • Figure 7.21: Asia-Pacific: Market Dynamics
  • Figure 7.22: Asia-Pacific: Carrier Screening Market (by Country), 2018 and 2029
  • Figure 7.23: China: Carrier Screening Market, 2018-2029
  • Figure 7.24: Japan: Carrier Screening Market, 2018-2029
  • Figure 7.25: Australia: Carrier Screening Market, 2018-2029
  • Figure 7.26: India: Carrier Screening Market, 2018-2029
  • Figure 7.27: South Korea: Carrier Screening Market, 2018-2029
  • Figure 7.28: Singapore: Carrier Screening Market, 2018-2029
  • Figure 7.29: Rest-of-the-Asia-Pacific: Carrier Screening Market, 2018-2029
  • Figure 7.30: Latin America: Carrier Screening Market, (2018-2029)
  • Figure 7.31: Latin America: Market Dynamics
  • Figure 7.32: Latin America: Carrier Screening Market (by Country), 2018 and 2029
  • Figure 7.33: Brazil: Carrier Screening Market, 2018-2029
  • Figure 7.34: Mexico: Carrier Screening Market, 2018-2029
  • Figure 7.35: Rest-of-Latin America: Carrier Screening Market, 2018-2029
  • Figure 7.36: Rest-of-the-World: Carrier Screening Market, 2018-2029
  • Figure 8.1: Shares of Key Company Profiles
  • Figure 8.2: 23and Me, Inc.: Overall Product Portfolio
  • Figure 8.3: 23andMe Inc.: SWOT Analysis
  • Figure 8.4: BGI Product Offerings for Global Carrier Screening Market
  • Figure 8.5: BGI: SWOT Analysis
  • Figure 8.6: CENTOGENE AG: Overall Product Portfolio
  • Figure 8.7: CENTOGENE AG: SWOT Analysis
  • Figure 8.8: Eurofins Scientific: Overall Product Portfolio
  • Figure 8.9: Eurofins Scientific: Overall Financials, 2016-2018
  • Figure 8.10: Eurofins Scientific: Revenue (by Region), 2016-2018
  • Figure 8.11: Eurofins Scientific: SWOT Analysis
  • Figure 8.12: Gene by Gene: Overall Product Portfolio
  • Figure 8.13: Gene by Gene: SWOT Analysis
  • Figure 8.14: GenMark Diagnostics, Inc.: Overall Product Portfolio
  • Figure 8.15: GenMark Diagnostics, Inc.: Overall Financials, 2016-2018
  • Figure 8.16: GenMark Diagnostics, Inc.: R&D Expenditure, 2016-2018
  • Figure 8.17: GenMark Diagnostics, Inc.: SWOT Analysis
  • Figure 8.18: Illumina, Inc.: Overall Product Portfolio
  • Figure 8.19: Illumina, Inc.: Overall Financials, 2016-2018
  • Figure 8.20: Illumina, Inc.: Revenue (by Segment), 2016-2018
  • Figure 8.21: Illumina, Inc.: Revenue (by Region), 2016-2018
  • Figure 8.22: Illumina, Inc.: R&D Expenditure, 2016-2018
  • Figure 8.23: Illumina, Inc.: SWOT Analysis
  • Figure 8.24: Invitae Corporation: Overall Product Portfolio
  • Figure 8.25: Invitae Corporation: Overall Financials, 2016-2018
  • Figure 8.26: Invitae Corporation: Revenue (by Region), 2016-2018
  • Figure 8.27: Invitae Corporation: R&D Expenditure, 2016-2018
  • Figure 8.28: Invitae Corporation: SWOT Analysis
  • Figure 8.29: Laboratory Corporation of America Holdings: Overall Product Portfolio
  • Figure 8.30: Laboratory Corporation of America Holdings: Overall Financials, 2016-2018
  • Figure 8.31: Laboratory Corporation of America Holdings: Revenue (by Segment), 2016-2018
  • Figure 8.32: Laboratory Corporation of America Holdings: Revenue (by Region), 2018
  • Figure 8.33: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 8.34: Myriad Genetics, Inc.: Overall Product Portfolio
  • Figure 8.35: Myriad Genetics, Inc.: Overall Financials, 2016-2018
  • Figure 8.36: Myriad Genetics, Inc.: Revenue (by Business Segment), 2016-2018
  • Figure 8.37: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 8.38: Natera, Inc.: Overall Product Portfolio
  • Figure 8.39: Natera, Inc.: Overall Financials, 2016-2018
  • Figure 8.40: Natera, Inc.: Revenue (by Business Segment), 2016-2018
  • Figure 8.41: Natera, Inc.: R&D Expense, 2016-2018
  • Figure 8.42: Natera, Inc.: SWOT Analysis
  • Figure 8.43: Pathway Genomics Corporation: Overall Product Portfolio
  • Figure 8.44: Pathway Genomics Corporation: SWOT Analysis
  • Figure 8.45: Product Portfolio: Quest Diagnostics Incorporated
  • Figure 8.46: Quest Diagnostics Incorporated: Overall Financials, 2016-2018
  • Figure 8.47: Quest Diagnostics Incorporated: Revenue (by Segment), 2016-2018
  • Figure 8.48: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 8.49: Sema4: Overall Product Portfolio
  • Figure 8.50: Sema4: SWOT Analysis
  • Figure 8.51: Thermo Fisher Scientific Inc.: Overall Product Portfolio
  • Figure 8.52: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
  • Figure 8.53: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2016-2018
  • Figure 8.54: Thermo Fisher Scientific Inc.: Revenue (by Region), 2016-2018
  • Figure 8.55: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
  • Figure 8.56: Thermo Fisher Scientific Inc.: SWOT Analysis
Back to Top